Meriofert

Luteinising Hormone (Human); Follicle-Stimulating Hormone, the active ingredient in Meriofert, is a gonadotropin presented as an injection for intramuscular or subcutaneous use. It treats infertility related to hypogonadotropic hypogonadism and supports ovulation in assisted reproductive technology.

GNH USA supplies Meriofert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meriofert is a gonadotropin used to address reproductive disorders that involve insufficient endogenous LH and FSH activity. - Infertility due to hypogonadotropic hypogonadism: supports follicular development and ovulation in patients with deficient gonadotropin secretion. - Assisted reproductive technology (e.g., IVF): enhances oocyte maturation and improves cycle outcomes when combined with controlled ovarian stimulation. - Induction of ovulation: facilitates the development of a dominant follicle to trigger ovulation in anovulatory women.

Adverse reactions may occur with any injectable gonadotropin therapy.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the administration site. - Abdominal discomfort: transient bloating or mild cramping. - Headache: occasional mild to moderate headache. - Nausea: occasional feeling of queasiness.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome: excessive ovarian response requiring medical monitoring. - Thromboembolic events: rare clot formation in veins or arteries. - Severe allergic reaction: anaphylaxis or systemic urticaria. - Multiple pregnancy: increased risk of twins or higher-order gestations.

Prior to initiating therapy, clinicians should evaluate patient suitability and monitor response closely. - Assess baseline gonadotropin levels: confirm deficiency before treatment. - Monitor ovarian response: use ultrasound and hormone assays to avoid overstimulation. - Review contraindications: avoid in active malignancy or uncontrolled endocrine disorders. - Counsel on signs of hyperstimulation: educate patients to report abdominal pain, rapid weight gain, or shortness of breath. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions may modify efficacy or safety of Meriofert.

Major Interactions (Avoid): - Concurrent use with GnRH agonists that may cause excessive gonadotropin surge. - Use with estrogen‑containing contraceptives: may reduce intended ovulatory effect. - Co‑administration with anticoagulants: increased risk of injection‑site bleeding.

Moderate Interactions (Monitor Closely): - Combined ovarian stimulation protocols: require close hormone level monitoring. - Concomitant corticosteroids: may mask early allergic reactions. - Use with other fertility agents: adjust dosing based on response.